Clinical Trial Update: Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating persistence of anti-meningococcal bactericidal antibodies in adolescents previously vaccinated with a MenACWY conjugate vaccine. Result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Meningitis

Drugs mentioned

• Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Meningitis | Phase 3 | Status: COMPLETED | Results posted: 2014-01-22